Skip to main content

Table 1 Inhibited tumor growth and body/heart weights after an intrapleural injection of ZOL

From: An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol

Agent (μg/mouse) Day of agent administration Tumor weight (average ± SE) (mg) Body weight (average ± SE) (g) Heart weight (average ± SE) (mg)
Experiment 1 (assessment of tumor weight: day 28)
 PBS 3 491.1 ± 68.4** ND ND
 ZOL (80 μg) 3 0** ND ND
Experiment 2 (assessment of tumor weight: day 28)
 PBS 3 384.8 ± 36.8** 15.9 ± 5.1** 99.8 ± 5.2*
 ZOL (40 μg) 3 19.8 ± 7.2** 18.9 ± 0.24** 114.5 ± 3.6*
Experiment 3 (assessment of tumor weight: day 35)
 PBS 3 197.7 ± 22.9** 18.5 ± 1.0 123.2 ± 5.8
 ZOL (40 μg) 3 2.5 ± 1.2** 19.6 ± 0.3 129.5 ± 3.5*
 ZOL (15 μg) 3 79.3 ± 13.2** 19.2 ± 0.2 116.6 ± 3.4*
Experiment 4 (assessment of tumor weight: day 28)
 PBS 10 377.9 ± 13.3* 16.1 ± 0.4* ND
 ZOL (40 μg) 10 188.6 ± 62.1* 19.2 ± 0.5* ND
  1. BALB/c nude mice were inoculated with human mesothelioma, MSTO-211H cells (experiment 1, 2 and 4) or EHMES-10 (experiment 3) (1 × 106/mouse), in the intrapleural cavity and were injected with PBS or ZOL (100 μl in volume) on day 3 or 10. Tumor weights were measured on the indicated day and the averages with standard errors are shown (experiment 1; n = 5, experiment 2; n = 6, experiment 3; n = 7, experiment 4; n = 7)
  2. ** P < 0.01; * P < 0.05 (experiment 3; difference of tumor weights is statistically significant in any of two groups and that of heart weights is statistically significant only between ZOL 15 μg- and ZOL 40 μg-injected groups)